BBOT Q1 net loss widens to $42.1M; cash $388.9M funds ops into 2028; pipeline shows early efficacy

BridgeBio Oncology Therapeutics, Inc.

2026-Q1 EPS reported -$526.11

Net loss $42.1M vs $22.1M YoY; R&D spend $39.8M on advancing three RAS programs.
Cash, equivalents and marketable securities $388.9M as of March 31, 2026; runway into 2028.
BBO-8520 monotherapy ORR 65% in KRAS G12C NSCLC; BBO-11818 partial response in pancreatic cancer.
BBO-10203 achieved target engagement with no hyperglycemia; clinical benefit in CRC and HR+ BC.
Pedro Beltran appointed CEO, Idan Elmelech COO effective April 20, 2026; Neil Kumar Executive Chairman.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

BridgeBio Oncology Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $42.1 million for the first quarter of 2026 compared to $22.1 million for the first qu.

Period: the first quarter ended March 31, 2026
Net income: Net loss was $42.1 million for the first quarter of 2026 compared to $22.1 million for the first qu
Result: reported results

Exact text from the filing

BridgeBio Oncology Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

BridgeBio Oncology Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-219801

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.